2017与2015版GOLD报告比较:对分组和结局的影响
该前瞻性队列纳入819例慢阻肺患者(84%男性),随访平均5年,比较2015与2017版GOLD ABCD分组。2017版使C和D组比例减半(20.5% vs 11.2%和24.6% vs 12.9%,P<0.001),Charlson共病评分在各组趋于一致,BODE指数和死亡风险在B与D组相近,2015版对死亡风险预测更好。
要点
- 2017版GOLD使C和D组患者比例较2015版减半(P<0.001)。
- 2017版下Charlson共病评分在各组趋于一致,B与D组BODE指数和死亡风险相近。
- 2015版GOLD系统对死亡风险的预测优于2017版。
核心结论
- 2017版GOLD ABCD分类较2015版显著将患者从C和D组重新分配至A和B组。
- 新分类使Charlson共病评分在各组趋于一致,并缩小B与D组间BODE指数差异,使两组死亡风险相似。
- 2015版GOLD系统对死亡风险的预测优于2017版。
研究设计与样本
- 前瞻性队列研究,纳入西班牙和美国门诊819例慢阻肺患者(84%男性),平均随访5年。
- 测定人体测量学、FEV1%、mMRC呼吸困难评分、门诊和住院急性加重、BODE指数和Charlson指数。
- 分别按2015和2017版GOLD ABCD系统分类,比较同一患者的重分类及对BODE、Charlson分布和死亡风险的影响。
主要发现
- 2017版较2015版使C组比例从20.5%降至11.2%,D组从24.6%降至12.9%(P<0.001)。
- 2015版中D组Charlson评分高于B组,2017版中两组趋于相似。
- 2017版中B和D组的BODE指数和死亡风险高于A和C组,但B与D组间死亡风险相似。
- 2015版GOLD系统对死亡风险的预测优于2017版。
临床怎么用
- 临床采用2017版GOLD分组时,应意识到C和D组患者比例减少,部分患者被重新归入A和B组。
- 2017版下B组与D组的死亡风险相近,提示B组患者亦需关注不良结局风险。
- 2015版GOLD分组对死亡风险预测更优,临床风险评估时可参考既往版本分组信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) document has modified the grading system directing pharmacotherapy, but how this relates to the previous one from 2015 and to comorbidities, hospitalizations, and mortality risk is unknown. OBJECTIVES: The aim of this study was to evaluate the changes in the GOLD groups from 2015 to 2017 and to assess the impact on severity, comorbidities, and mortality within each group. METHODS: We prospectively enrolled and followed, for a mean of 5 years, 819 patients with chronic obstructive pulmonary disease (84% male) in clinics in Spain and the United States. We determined anthropometrics, lung function (FEV1%), dyspnea score (modified Medical Research Council scale), ambulatory and hospital exacerbations, and the body mass index, obstruction, dyspnea, and exercise capacity (BODE) and Charlson indexes. We classified patients by the 2015 and 2017 GOLD ABCD system, and compared the differential realignment of the same patients. We related the effect of the reclassification in BODE and Charlson distribution as well as chronic obstructive pulmonary disease and all-cause mortality between the two classifications. MEASUREMENTS AND MAIN RESULTS: Compared with 2015, the 2017 grading decreased by half the proportion of patients in groups C and D (20.5% vs. 11.2% and 24.6% vs. 12.9%; P < 0.001). The distribution of Charlson also changed, whereas group D was higher than B in 2015, they become similar in the 2017 system. In 2017, the BODE index and risk of death were higher in B and D than in A and C. The mortality risk was better predicted by the 2015 than the 2017 system. CONCLUSIONS: Compared with 2015, the GOLD ABCD 2017 classification significantly shifts patients from grades C and D to categories A and B. The new grading system equalizes the Charlson comorbidity score in all groups and minimizes the differences in BODE between groups B and D, making the risk of death similar between them.
引用
- Cabrera López C, Casanova Macario C, Marín Trigo JM, et al. Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. Am J Respir Crit Care Med. 2018. PMID: 29099607. doi:10.1164/rccm.201707-1363OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。